De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients. Issue 2 (20th April 2021)

• Record Type: Journal Article
• Authors: Jain, Rashmi; Habal, Marlena V.; Clerkin, Kevin J.; Latif, Farhana; Restaino, Susan W.; Zorn, Emmanuel; Takeda, Koji; Naka, Yoshifumi; Yuzefpolskaya, Melana; Farr, Maryjane A.; Colombo, Paolo C.; Sayer, Gabriel T.; Uriel, Nir; Topkara, Veli K.
• Is Part Of: ASAIO journal. Volume 68:Issue 2(2022)
• Page Start: 226
• Page End: 232
• Publication Date: 2021-04-20
• Subjects: left ventricular assist device -- HLA antigens -- allosensitization -- heart transplantation; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001451
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Left ventricular assist devices (LVADs) are associated with the development of antihuman leukocyte antigen (HLA) antibodies, which can create a challenge for future transplantation in these patients. The differential effects of Heartmate 3 (HM3) versus Heartmate II (HMII) on de novo HLA allosensitization remain unknown. Patients who underwent HMII or HM3 implantation and had no prior HLA antibodies by solid-phase assay (Luminex) testing were included in this study. Complement-dependent cytotoxicity (CDC) panel reactive antibody (PRA) levels and Luminex antibody profiles were followed until cardiac transplantation, device explantation, or death. Electronic medical records were reviewed to examine posttransplant outcomes. Thirty-eight HM3 and 34 HMII patients with complete data were followed for 1.5 ± 1.1 years on device support. HM3 and HMII groups had similar age at implant, female gender, ischemic heart failure etiology, bridge strategy at implant, as well as intraoperative and postoperative transfusion requirements. 39.5% of HM3 and 47.1% of HMII patients developed detectable HLA antibodies by Luminex testing ( p = 0.516). Development of high-level (mean fluorescence intensity >10, 000) antibodies was significantly lower in HM3 than HMII patients (5.3 vs. 20.6%, p = 0.049). CDC PRA testing showed fewer HM3 patients with a positive result (PRA > 0%) than HMII patients (39.4 vs. 70.0%, p = 0.015). Among transplanted patients, those who had developed de novo sensitization on LVAD support showed a trend toward incidence of moderate to severe grade rejection compared with unsensitized patients (23.8 vs. 4.8%, p = 0.078). HM3 is associated with lower risk of de novo HLA sensitization compared with HMII.